Tilray Net Income Over Time
| TLRY Stock | USD 7.58 0.53 7.52% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tilray Performance and Tilray Correlation. Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tilray. If investors know Tilray will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tilray assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (23.53) | Revenue Per Share | Quarterly Revenue Growth 0.031 | Return On Assets | Return On Equity |
Understanding Tilray Inc requires distinguishing between market price and book value, where the latter reflects Tilray's accounting equity. The concept of intrinsic value - what Tilray's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Tilray's price substantially above or below its fundamental value.
Please note, there is a significant difference between Tilray's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tilray is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tilray's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Tilray Inc and related stocks such as Evotec SE ADR, Alvotech, and Harrow Health Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EVO | (12.8 M) | 6.7 M | 2.5 M | (25.4 M) | (7 M) | 16.5 M | 27.5 M | 24.3 M | 84.2 M | 38.2 M | 6.3 M | 215.5 M | (175.7 M) | (83.9 M) | (196.1 M) | (176.5 M) | (167.6 M) |
| ALVO | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (170 M) | (101.5 M) | (513.6 M) | (551.7 M) | (231.9 M) | (208.7 M) | (219.1 M) |
| HROW | (46.2 K) | (954 K) | (5.4 M) | (7.6 M) | (10.1 M) | (15.9 M) | (19.1 M) | (12 M) | 14.6 M | 168 K | (3.4 M) | (18 M) | (14.1 M) | (24.4 M) | (17.5 M) | (15.7 M) | (14.9 M) |
| PAHC | 10.1 M | 7 M | 24.9 M | (3.1 M) | 60.3 M | 82.7 M | 64.6 M | 64.9 M | 54.7 M | 33.6 M | 54.4 M | 49.2 M | 32.6 M | 2.4 M | 48.3 M | 55.5 M | 58.3 M |
| NEOG | (1.1 M) | 22.5 M | 27.2 M | 28.2 M | 33.5 M | 36.6 M | 43.8 M | 63.1 M | 60.2 M | 59.5 M | 60.9 M | 48.3 M | (22.9 M) | (9.4 M) | (1.1 B) | (982.8 M) | (933.7 M) |
| DVAX | (26.7 M) | (48.6 M) | (69.9 M) | (66.7 M) | (90.7 M) | (106.8 M) | (112.4 M) | (95.2 M) | (158.9 M) | (152.6 M) | (75.2 M) | 76.7 M | 293.2 M | (6.4 M) | 27.3 M | 31.4 M | 33 M |
| AMPH | 7.8 M | 7.8 M | 18.1 M | 11.9 M | (10.7 M) | (2.8 M) | 10.5 M | 4.5 M | (5.7 M) | 48.9 M | 1.4 M | 62.1 M | 91.4 M | 137.5 M | 159.5 M | 183.4 M | 192.6 M |
| IMNM | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (10.6 M) | (17.1 M) | (24.7 M) | (36.9 M) | (106.8 M) | (293 M) | (263.7 M) | (250.5 M) |
| MAZE | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (100.4 M) | 52.2 M | 60.1 M | 63.1 M |
| NTLA | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (12.4 M) | (31.6 M) | (67.5 M) | (85.3 M) | (99.5 M) | (125.6 M) | (259.7 M) | (474.2 M) | (481.2 M) | (519 M) | (467.1 M) | (443.8 M) |
Tilray Inc and related stocks such as Evotec SE ADR, Alvotech, and Harrow Health Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Tilray Inc financial statement analysis. It represents the amount of money remaining after all of Tilray Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Tilray Inc | TLRY |
| Classification | Cannabis |
| Business Address | 265 Talbot Street |
| Exchange | NASDAQ Exchange |
USD 7.58
Additional Tools for Tilray Stock Analysis
When running Tilray's price analysis, check to measure Tilray's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tilray is operating at the current time. Most of Tilray's value examination focuses on studying past and present price action to predict the probability of Tilray's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tilray's price. Additionally, you may evaluate how the addition of Tilray to your portfolios can decrease your overall portfolio volatility.